Impact of neoadjuvant immunotherapy on postoperative complications after oncologic surgery
Date:
This study examines the impact of neoadjuvant immunotherapy on postoperative complications in various cancers. We analyzed data from over 950,000 cases involving curative-intent cancer surgery between 2010 and 2020, 0.5% of which were preceded by immunotherapy. Our findings indicate that neoadjuvant immunotherapy does not significantly increase postoperative major morbidity, suggesting surgery in the setting of neoadjuvant immunotherapy is safe.
Recommended citation: Shou M, Habib DRS, Idrees K, Khan A. Impact of neoadjuvant immunotherapy on postoperative complications after oncologic surgery. Oral presentation at: Society of Asian Academic Surgeons Annual Meeting; September 6, 2024; New Orleans, LA, USA.
